Showing results (151-160 of 286) with videos related to

Sort By:
Pageof 29
Cancer Letters|March 28, 2008
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangementHirokazu Ogino, Seiji Yano, Soji Kakiuchi, et al.
Cancer Research|February 6, 2013
EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibitionTakayuki Nakagawa, Shinji Takeuchi, Tadaaki Yamada, et al.
Internal Medicine (Tokyo, Japan)|September 4, 2024
Effectiveness of Additional Immunosuppressive Drugs for Corticosteroid-refractory Immune Checkpoint Inhibitor-induced Myocarditis: Two Case ReportsHiroyuki Sakaguchi, Shigeki Nanjo, Shigeki Sato, et al.
The Journal of Medical Investigation : JMI|September 29, 2017
The case of double primary lung adenocarcinomas with an EGFR mutation and ALK translocation successfully treated with alectinib at the post-surgical recurrenceYoshio Tsunezuka, Nobuyoshi Tanaka, Hideki Fujimori, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 22, 2012
[A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan]Kaname Yamashita, Daisuke Ishikawa, Shigeki Nanjo, et al.
Nature Communications|July 10, 2015
Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2Yue Zhou, Naoki Yamada, Tomohiro Tanaka, et al.
Oncogene|January 20, 2018
Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancersHiroshi Kotani, Yuta Adachi, Hidenori Kitai, et al.
The Journal of Medical Investigation : JMI|September 29, 2017
Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocolShinji Takeuchi, Kenichi Yoshimura, Tadami Fujiwara, et al.
Experimental Cell Research|January 15, 2004
Ebselen inhibits tumor necrosis factor-alpha-induced c-Jun N-terminal kinase activation and adhesion molecule expression in endothelial cellsMasanori Yoshizumi, Yoshiko Fujita, Yuki Izawa, et al.
Oncology Research|October 8, 2009
A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient miceShinsaku Otsuka, Masaki Hanibuchi, Kenji Ikuta, et al.
Pageof 29